Needham Raises Autolus Target to $11, Sees Strong Upside Into 2026
Needham boosts Autolus Therapeutics price target to $11, keeps Buy rating, and highlights breakeven potential and upside from obe-cel and Aucatzyl.
/ 2 items
Needham boosts Autolus Therapeutics price target to $11, keeps Buy rating, and highlights breakeven potential and upside from obe-cel and Aucatzyl.
NICE recommends Autolus AUCATZYL (obecabtagene autoleucel) for adults 26+ with relapsed/refractory B-cell acute lymphoblastic leukemia in England and Wales.